Incision-Free Ablative
Intervention, with Vision
Transurethral Ultrasound Ablation of the Prostate that aims to maintain quality of life and provides the ability to treat a broad spectrum of patients.
Incision-Free Ablative
The CAPTAIN trial marks an important milestone in prostate cancer treatment. As the first multi-center randomized controlled trial to successfully enroll to target while directly comparing a novel technology with robotic radical prostatectomy, it provides new evidence for men with localized prostate cancer.
In this head-to-head study, Profound’s MRI-guided TULSA Procedure™ met its primary safety endpoint, demonstrating a statistically significant improvement in the preservation of erectile function together with urinary continence at six months compared with robotic radical prostatectomy.
Watch this video to learn more about the CAPTAIN trial results and what they mean for the future of prostate cancer treatment.
Flexible
The TULSA Procedure offers customizable treatment planning and 360-degree targeting capability, providing physicians with the flexibility to ablate prescribed tissue volumes in men with localized prostate cancer, prostate cancer combined with obstructive BPH, localized radiorecurrent prostate cancer, or large volume BPH.
Precise
Real-time MRI temperature monitoring enables gradual, gentle heating of prostate tissue to achieve cell death, degree by degree. TULSA-PRO uses this closed-loop feedback to ensure ablation accuracy by automatically adjusting the energy throughout the procedure.
Durable
The TULSA Procedure has demonstrated durable efficacy and safety, supported by 67+ peer-reviewed publications up to 5-year clinical outcomes.
Safe
Patient safety is paramount in the TULSA Procedure. With MRI guidance, real-time monitoring, and precise control, the treatment is administered accurately, minimizing complications and prioritizing the well-being of the patient.
Have Questions
106729B